Orphazyme CEO departs for Leo Pharma as both companies face major restructurings
Someone else, it seems, will get the opportunity of trying to steer Orphazyme back to its former memeland glory.
In a bit of Danish biotech musical chairs, Orphazyme CEO Christophe Bourdon is leaving the rare disease biotech to become CEO of the dermatology-focused Leo Pharma, the companies announced. Bourdon’s departure, set for April 1, will come barely a year after he joined, although it was not an uneventful one.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.